Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28861068 | 0.86 | SLC6A2 (0.47) | L3MBTL1MITFSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1415727 | 0.84 | SLC6A2 (0.63) | MITFSLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL27505917 | 0.84 | SLC6A2 (0.63) | MITFSLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL6936570 | 0.84 | SLC6A2 (0.63) | MITFSLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL28231989 | 0.81 | SIGMAR1 (0.46) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15901734 | 0.80 | CHIT1 (0.43) | L3MBTL1MITFSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15901735 | 0.80 | CHIT1 (0.43) | L3MBTL1MITFSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29050285 | 0.80 | ALDH1A1 (0.44) | ALDH1A1POLBGBA1 | |
| SCHEMBL27668148 | 0.78 | ALDH1A1 (0.45) | ALDH1A1POLBGBA1 | |
| Pyridine SCHEMBL28173600 | 0.77 | SLC6A2 (0.55) | MITFSLC6A2SLC6A4SLC6A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-0691962-B1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AG (DE) | 2000-09-13 | — | — | EP | disclosed |
| US-5622953-A | DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0691962-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
| US-4663456-A | 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | L3MBTL1 4111/4885MITF 4803/4885SLC6A2 3677/4885 |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | L3MBTL1 2672/4885MITF 716/4885SLC6A2 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.